WHO ICTRP trial
Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory…
JPRN-jRCT2041220067 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2041220067 |
|---|---|
| Public title | Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
| Scientific title | [M20-429] A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms |
| Primary sponsor | Yamagishi Chika |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Countries | US;Japan;Australia;Japan;Belgium;Japan;Canada;Japan;Czechia;Japan;France;Japan;Germany;Japan;Israel;Japan;Italy;Japan;Republic of Korea;Japan;Netherlands;Japan;Spain;Japan;Taiwan;Japan;Turkey;Japan |
| Conditions | Mature B-cell lymphomas |
| Interventions | Participants will receive subcutaneous (SC) epcoritamab in 28 day cycles. |
| Registration date | Apr 10, 2022 |
| Target size | 15 |
| Secondary IDs | NCT05206357 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: